{"id":6941,"date":"2020-05-19T13:07:28","date_gmt":"2020-05-19T20:07:28","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=6941"},"modified":"2021-03-18T13:08:51","modified_gmt":"2021-03-18T20:08:51","slug":"cross-neutralization-of-sars-cov-2-by-a-human-monoclonal-sars-cov-antibody","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/05\/19\/cross-neutralization-of-sars-cov-2-by-a-human-monoclonal-sars-cov-antibody\/","title":{"rendered":"Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody"},"content":{"rendered":"<ul>\n<li>Pinto et al. describe an antibody(S309) that neutralizes SARS-CoV-2. This antibody was identified from memory B cells of a person infected with SARS-CoV in 2003. The S309 antibody functions by engaging the SARS-CoV-2 spike glycoprotein receptor-binding domain, the region that facilitates the SARS-CoV-2 virus\u2019 entry into host cells.<\/li>\n<li>These findings can be used to facilitate development of S309-and S309-containing antibody therapies for prophylactic use in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.<\/li>\n<\/ul>\n<p><em>Pinto et al. (May18, 2020). Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. <a href=\"https:\/\/doi.org\/10.1038\/s41586-020-2349-y\">https:\/\/doi.org\/10.1038\/s41586-020-2349-y<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pinto et al. describe an antibody(S309) that neutralizes SARS-CoV-2. This antibody was identified from memory B cells of a person infected with SARS-CoV in 2003. The S309 antibody functions by engaging the SARS-CoV-2 spike glycoprotein receptor-binding domain, the region that facilitates the SARS-CoV-2 virus\u2019 entry into host cells. These findings can be used to facilitate&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/05\/19\/cross-neutralization-of-sars-cov-2-by-a-human-monoclonal-sars-cov-antibody\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[19],"class_list":["post-6941","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=6941"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6941\/revisions"}],"predecessor-version":[{"id":6942,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6941\/revisions\/6942"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=6941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=6941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=6941"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=6941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}